Icagen, Inc. and Pfizer Inc. Initiate Nav 1.7 Phase I Multiple Ascending Dose Study

RESEARCH TRIANGLE PARK, N.C., June 20, 2011 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today provided an update on its sodium channel program for pain and related disorders which is being conducted in collaboration with Pfizer. Icagen and Pfizer have initiated a multiple ascending dose study of the lead compound in the collaboration, which targets the ion channel Nav 1.7.

Back to news